Literature DB >> 9880951

[Treatment of depression and sleep disorders. Significance of serotonin and L-tryptophan in pathophysiology and therapy].

D Riemann1, U Vorderholzer.   

Abstract

Since the nineteen-sixties, L-tryptophan has been used to treat depression and sleep-disorders. It appears to be suitable for the the treatment of mild forms of depression and of special forms, such as depressive mood associated with the climacteric. In a subgroup of patients, L-tryptophan can help re-establish a physiological sleep pattern in patients with chronic sleep problems. In the case of dependence on hypnotics, L-tryptophan can ease withdrawal symptoms. Recently published studies have shown that acute L-tryptophan depletion can lead to impairment of sleep continuity, and, in patients with an appropriate predisposition, to brief reversible depressive moods. In 1989, oral preparations of L-tryptophan were reported to precipitate the eosinophilia-myalgia syndrome (EMS). However, the real culprit proved to be contaminations of the basic substance of L-tryptophan which are no longer present in measurable amounts in the preparations now available on the market. Today, improved purification and analytic methods ensure the harmlessness of L-tryptophan preparations. In comparison with synthetic antidepressants and hypnotics, L-tryptophan is characterized by a particular low level of side-effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9880951

Source DB:  PubMed          Journal:  Fortschr Med        ISSN: 0015-8178


  2 in total

1.  Melatonin and tryptophan affect the activity-rest rhythm, core and peripheral temperatures, and interleukin levels in the ringdove: changes with age.

Authors:  Sergio D Paredes; Ana María Marchena; Ignacio Bejarano; Javier Espino; Carmen Barriga; Rubén V Rial; Russel J Reiter; Ana B Rodríguez
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-02-10       Impact factor: 6.053

2.  L -5-Hydroxytryptophan treatment of sleep terrors in children.

Authors:  Oliviero Bruni; Raffaele Ferri; Silvia Miano; Elisabetta Verrillo
Journal:  Eur J Pediatr       Date:  2004-05-14       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.